Exosomal PD-L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B-cell lymphoma

被引:3
作者
Zeng, Hui [1 ]
Wang, Jinfeng [2 ,3 ]
Xu, Biaoming [1 ]
Deng, Hongyu [2 ,3 ]
Peng, Mingjing [2 ,3 ]
Deng, Rilin [4 ]
Shang, Song [2 ,3 ]
Hu, Qi [1 ]
Li, Junjun [2 ,3 ]
Lin, Jinguan [2 ,3 ]
Zhu, Haizhen [2 ,3 ,4 ]
Li, Yajun [2 ,3 ,5 ,6 ]
Zuo, Chaohui [1 ,2 ,4 ,5 ,6 ]
机构
[1] Univ South China, Grad Collaborat Training Base Hunan Canc Hosp, Hengyang, Peoples R China
[2] Cent South Univ, Xiangya Sch Med, Translat Med Res Ctr Liver Canc, Affiliated Canc Hosp,Lab Digest Oncol,Hunan Canc I, Changsha 410013, Hunan, Peoples R China
[3] Cent South Univ, Hunan Canc Hosp, Hunan Canc Inst, Changsha 410013, Hunan, Peoples R China
[4] Cent South Univ, Hunan Canc Hosp, Hunan Canc Inst, Hunan Prov Key Lab Med Virol, Changsha 410013, Hunan, Peoples R China
[5] Cent South Univ, Xiangya Sch Med, Translat Med Res Ctr Liver Canc, Hunan Canc Inst,Lab Digest Oncol,Affiliated Canc H, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
[6] Cent South Univ, Hunan Canc Hosp, Hunan Canc Inst, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
exosomes; PD-L1; gastric diffuse large B-cell lymphoma; immune microenvironment; immunosuppression; DEATH LIGAND 1; CANCER; BLOCKADE; BIOMARKERS; IMMUNITY;
D O I
10.3892/or.2023.8525
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastric diffuse large B-cell lymphoma (GDLBCL) is a common disease with an increasing incidence. However, the regulatory effect of exosomal programmed death-ligand 1 (PD-L1) on the immune microenvironment in GDLBCL is unclear. In the present study, the protein expression levels of exosomal PD-L1 in the supernatants of cultured diffuse large B-cell lymphoma (DLBCL) cells and the plasma of patients with GDLBCL was assessed using immunoblotting. Exosomes derived from DLBCL cells were cocultured with T lymphocytes or injected into tumor xenograft mice by tail vein injection. The relationship between the protein expression level of exosomal PD-L1 in the plasma and the clinical characteristics and immune microenvironmental parameters of GDLBCL was evaluated using immunoblotting and immunohistochemistry. High levels of exosomal PD-L1 were found in the supernatants of cultured DLBCL cells. Exosomes with high levels of PD-L1 promoted growth of tumors formed by DLBCL cells in vivo and inhibited the proliferation of T lymphocytes. Notably, the protein expression level of PD-L1 in plasma exosomes derived from GDLBCL patients was significantly higher than that of healthy individuals. High levels of PD-L1 in plasma exosomes were significantly associated with international prognostic index score, pathological type and advanced Lugano stage, which might lead to the poor prognosis of GDLBCL. Moreover, a high level of PD-L1 in plasma exosomes was significantly associated with an immunosuppressive microenvironment in GDLBCL. Therefore, the results of the present study indicated that exosomal PD-L1 inhibited the proliferation of T lymphocytes and promoted the formation of an immunosuppressive microenvironment in GDLBCL. High expression of exosomal PD-L1 may suggest a poor prognosis of GDLBCL, and exosomal PD-L1 in plasma may be a new diagnostic indicator for GDLBCL.
引用
收藏
页数:11
相关论文
共 53 条
  • [1] Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
    Andorsky, David J.
    Yamada, Reiko E.
    Said, Jonathan
    Pinkus, Geraldine S.
    Betting, David J.
    Timmerman, John M.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (13) : 4232 - 4244
  • [2] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
    Ansell, Stephen M.
    Lesokhin, Alexander M.
    Borrello, Ivan
    Halwani, Ahmad
    Scott, Emma C.
    Gutierrez, Martin
    Schuster, Stephen J.
    Millenson, Michael M.
    Cattry, Deepika
    Freeman, Gordon J.
    Rodig, Scott J.
    Chapuy, Bjoern
    Ligon, Azra H.
    Zhu, Lili
    Grosso, Joseph F.
    Kim, Su Young
    Timmerman, John M.
    Shipp, Margaret A.
    Armand, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) : 311 - 319
  • [3] Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
    Boussiotis, Vassiliki A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18) : 1767 - 1778
  • [4] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
    Brahmer, Julie R.
    Tykodi, Scott S.
    Chow, Laura Q. M.
    Hwu, Wen-Jen
    Topalian, Suzanne L.
    Hwu, Patrick
    Drake, Charles G.
    Camacho, Luis H.
    Kauh, John
    Odunsi, Kunle
    Pitot, Henry C.
    Hamid, Omid
    Bhatia, Shailender
    Martins, Renato
    Eaton, Keith
    Chen, Shuming
    Salay, Theresa M.
    Alaparthy, Suresh
    Grosso, Joseph F.
    Korman, Alan J.
    Parker, Susan M.
    Agrawal, Shruti
    Goldberg, Stacie M.
    Pardoll, Drew M.
    Gupta, Ashok
    Wigginton, Jon M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) : 2455 - 2465
  • [5] Recent advancements in the use of exosomes as drug delivery systems
    Bunggulawa, Edwin J.
    Wang, Wei
    Yin, Tieying
    Wang, Nan
    Durkan, Colm
    Wang, Yazhou
    Wang, Guixue
    [J]. JOURNAL OF NANOBIOTECHNOLOGY, 2018, 16
  • [6] PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
    Chen, Benjamin J.
    Chapuy, Bjoern
    Jing Ouyang
    Sun, Heather H.
    Roemer, Margaretha G. M.
    Xu, Mina L.
    Yu, Hongbo
    Fletcher, Christopher D. M.
    Freeman, Gordon J.
    Shipp, Margaret A.
    Rodig, Scott J.
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (13) : 3462 - 3473
  • [7] Elements of cancer immunity and the cancer-immune set point
    Chen, Daniel S.
    Mellman, Ira
    [J]. NATURE, 2017, 541 (7637) : 321 - 330
  • [8] Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
    Chen, Gang
    Huang, Alexander C.
    Zhang, Wei
    Zhang, Gao
    Wu, Min
    Xu, Wei
    Yu, Zili
    Yang, Jiegang
    Wang, Beike
    Sun, Honghong
    Xia, Houfu
    Man, Qiwen
    Zhong, Wenqun
    Antelo, Leonardo F.
    Wu, Bin
    Xiong, Xuepeng
    Liu, Xiaoming
    Guan, Lei
    Li, Ting
    Liu, Shujing
    Yang, Ruifeng
    Lu, Youtao
    Dong, Liyun
    McGettigan, Suzanne
    Somasundaram, Rajasekharan
    Radhakrishnan, Ravi
    Mills, Gordon
    Lu, Yiling
    Kim, Junhyong
    Chen, Youhai H.
    Dong, Haidong
    Zhao, Yifang
    Karakousis, Giorgos C.
    Mitchell, Tara C.
    Schuchter, Lynn M.
    Herlyn, Meenhard
    Wherry, E. John
    Xu, Xiaowei
    Guo, Wei
    [J]. NATURE, 2018, 560 (7718) : 382 - +
  • [9] Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo
    Chen, Zhenzhen
    You, Liangshun
    Wang, Lei
    Huang, Xianbo
    Liu, Hui
    Wei, Ju Ying
    Zhu, Li
    Qian, Wenbin
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
  • [10] Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
    Cheson, Bruce D.
    Ansell, Stephen
    Schwartz, Larry
    Gordon, Leo I.
    Advani, Ranjana
    Jacene, Heather A.
    Hoos, Axel
    Barrington, Sally F.
    Armand, Philippe
    [J]. BLOOD, 2016, 128 (21) : 2489 - 2496